ABAna Babic

Ana Babic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Babic has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Mats and Methods from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

  • Open Access

    Supplementary Mats and Methods from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

  • Open Access

    Data from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

    Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

  • A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

    Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

  • Associations between common contraceptive use and circulating inflammatory biomarkers

    by Jennifer M Mongiovi, Ana Babic, Naoko Sasamoto, Amy L Shafrir, Tianyi Huang, Mary K Townsend, Lauren C Peres, Shelley S Tworoger, Kathryn L Terry

    Ovarian cancer incidence has declined in recent decades, due in part to oral contraceptive (OC) use and tubal ligation. However, intrauterine device (IUD) use has increasingly replaced OC use. As ovarian cancer is an inflammation-related disease, we examined the association of OC use, IUD use, and tubal ligation with plasma levels of C-reactive protein (CRP), interleukin 6 (IL-6), and soluble tumor necrosis factor α receptor 2 (sTNFR2), in the Nurses’ Health Study (NHS) and NHSII. After adjusting for reproductive, hormonal, and lifestyle factors, and mutual adjustment for other methods of contraception, there were no differences in inflammatory markers between ever and never use of each method. However, CRP levels decreased from an average 30.4% (-53.6, 4.4) with every 5 years since initial IUD use (P-trend=0.03), while CRP increased an average 9.9% (95% CI: 5.7, 14.3) with every 5 years of use of OC (P-trend<0.0001) as well as differences by BMI and menopausal status. Our results suggest IUD use and tubal ligation are not associated with higher circulating inflammatory markers long term, although long duration of OC use may increase generalized inflammation, which may in part explain why its protective effect wanes over time.